CUE - Cue Biopharma GAAP EPS of -$0.37 misses by $0.06 revenue of $0.15M beats by $0.05M
2023-03-21 16:28:48 ET
- Cue Biopharma press release ( NASDAQ: CUE ): Q4 GAAP EPS of -$0.37 misses by $0.06 .
- Revenue of $0.15M (-98.2% Y/Y) beats by $0.05M .
- Research and development expenses were $11.3 million and $11.5 million for the three months ended December 31, 2022 and 2021,
- General and administrative expenses were $3.7 million and $4.7 million for the three months ended December 31, 2022 and 2021
- As of December 31, 2022, the Company had approximately $76.3 million in cash, cash equivalents and marketable securities compared with $64.4 million as of December 31, 2021.
For further details see:
Cue Biopharma GAAP EPS of -$0.37 misses by $0.06, revenue of $0.15M beats by $0.05M